AMPA receptor and Amyloid beta PET imagings for elderly epilepsy and Alzheimer's disease.

An exploratory study to measure AMPA receptors and Amyloid beta densities with brain PET imaging in elderly epilepsy and in early Alzheimer's disease comparing with non-epileptic and non-dementia elderly controls.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031210312

Enrollment

Registered

2021-09-14

Start date

2021-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elderly epilepsy, Alzheimers disease, mild cognitive impairment elderly epilepsy, Alzheimers disease, mild cognitive impairment

Interventions

1) Vanous injection of [11C] K-2 (370MBq plus minus 10%) 2) Vanous injection of [18F] florbetapir(370MBq plus minus 10%) 3) Vanous injection of[11C] flumazenil(370MBq plus minus 10%)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Common inclusion criteria (2 is limited to elderly epilepsy and early AD/MCI. ) 1. 60 years older and under 90 years old at the registration. 2. A Patient who can express his or her intent to participate in this research with written documents by himself or herself. When a patient is unable to write his or her sign due to their ages and diseases, a substitute who was asked to write his or her sign by the patient can express intents to participate in this research with written documents in stead of the patient. Inclusion criteria for elderly epilepsy 1. Diagnosed with epilepsy according to the ILAE definition 2014. 2. Onset age of 60 years or older. Inclusion criteria for early AD and MCI Diagnosed as AD or MCI due to AD based on the NIA-AA criteria. Inclusion criteria for non-epileptic and non-dementia elderly control 1. Not diagnosed as dementia. 2. With amnesia, but with no trouble in their daily lives. 3. Not diagnosed as epilepsy.

Exclusion criteria

Exclusion criteria: Common exclusion criteria -excerpt- 1. History with open-scalpe brain surgery. 2. Diagnosed with brain tumor or brain trauma at the registration. 3. Unable to undergo 3T head MRI.

Design outcomes

Primary

Measure	Time frame
AMPAR_AImax for each group.	—

Secondary

Measure	Time frame
1. SUVR ration between [11C]K-2 and [11C]FMZ for each participant. 2. [11C] FMZ_AImax for each group. 3. [18F] florbetapir_AImax for each group. 4. Comparison among [18F] florbetapir, [11C]K-2 and [11C]FMZ imagings for each participant. 5. Frequency analysis of EEG on PET imaging (SPM analysis). 6. Dipole analysis of EEG on PET imaging. 7. Classification of each endpoint based on the accumulation of [18F] florbetapir.	—

Measure

Time frame

1. SUVR ration between [11C]K-2 and [11C]FMZ for each participant. 2. [11C] FMZ_AImax for each group. 3. [18F] florbetapir_AImax for each group. 4. Comparison among [18F] florbetapir, [11C]K-2 and [11C]FMZ imagings for each participant. 5. Frequency analysis of EEG on PET imaging (SPM analysis). 6. Dipole analysis of EEG on PET imaging. 7. Classification of each endpoint based on the accumulation of [18F] florbetapir.

—

Contacts

Public ContactHiroki Abe

Department of Physiology, Graduate School of Medicine, Yokohama City University

abhiroki@yokohama-cu.ac.jp+81-45-787-2579

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026